Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Key highlights: Demonstrated sustained improvements across symptomatic, clinical, endoscopic, histologic, and quality-of-life endpoints Benefits seen even in ~27% of patients who had failed prior biologics or advanced therapies Long-term safety profile consistent with prior findings no new safety signals Among patients continuing from blinded maintenance to the open-label extension, 12% reported serious adverse events, 7% discontinued due to adverse events Approved for UC and Crohns disease in 44 countries These results (from the LUCENT-3 extension) were shared at UEG Week 2025 in Berlin and mark a significant milestone in the pursuit of durable, steroid-free remission for IBD patients
Dosage by Fitzpatrick Skin Type This is the most important section of this guide
The available description does not mean the drug is no longer in shortage
Each subject may experience varying results depending on their age, diet, level of exercise, genetics, and other lifestyle factors
US$ 23.02
US$ 23.60
US$ 20.10
US$ 26.41
US$ 21.56
US$ 24.09
